Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS.
Glycyrrhizin (GL) at a dose of 400-1600 mg/day (7.2-30.8 mg/kg/day) was administered intravenously for a period of more than a month, on 6 separate occasions, to 3 hemophiliacs with acquired immune deficiency syndrome (AIDS). Human immunodeficiency virus type 1 (HIV-1) p24 antigen was detected at the beginning of 5 of the 6 treatment courses. Viral antigen was not detected at the end of or during 3 of the 5 treatment courses and decreased to a low level following the 2 other courses. These findings suggest that GL might inhibit HIV-1 replication in vivo.
Hattori
T
T
Second Department of Internal Medicine, Kumamoto University Medical School, Japan.
Ikematsu
S
S
Koito
A
A
Matsushita
S
S
Maeda
Y
Y
Hada
M
M
Fujimaki
M
M
Takatsuki
K
K
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes; D004341:Drug Evaluation; D015683:Gene Products, gag / Q000378:metabolism; D006034:Glycyrrhetinic Acid / Q000009:adverse effects / Q000627:therapeutic use; D019695:Glycyrrhizic Acid; D016655:HIV Core Protein p24; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014758:Viral Core Proteins / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D015683:Gene Products, gag; D016655:HIV Core Protein p24; D014758:Viral Core Proteins; D019695:Glycyrrhizic Acid; D006034:Glycyrrhetinic Acid